2025-08-21
CCRM Nordic makes its first venture investment, becoming a shareholder in Precision BioAnalytics. The collaboration aims to accelerate ATMP innovation through advanced molecular analysis and infrastructure.
In August 2025, CCRM Nordic announced its first strategic venture investment, becoming a shareholder in Precision BioAnalytics AB. This partnership brings together cutting-edge molecular analysis and infrastructure designed to accelerate the development of advanced therapy medicinal products (ATMPs) across the Nordics and beyond.
The collaboration builds on an already established relationship between the two organisations and highlights a shared vision: enabling smarter, faster and more effective translation of scientific discoveries into tangible patient therapies.
CCRM Nordic, based at GoCo Health Innovation City in Gothenburg, is developing next-generation infrastructure to eliminate bottlenecks in ATMP development. Precision BioAnalytics, founded by Professor Mikael Kubista, brings more than 30 years of leadership in molecular diagnostics, with over 300 scientific publications and contributions to international standards such as MIQE and ISO guidelines.
By joining forces, the two organisations will create a unique offering that combines infrastructure, translational science, and precision analytics. This strengthens support for:
Drug development
Clinical trials
Biomarker discovery
AI-driven diagnostics
Cell and gene therapy research
“Partnering with Precision BioAnalytics – and now investing in their future – is not just a service expansion. This is a statement of intent to co-create impact with some of the most exciting science in Europe,” said Fredrik Wessberg, CEO of CCRM Nordic.
“Their translational vision and infrastructure, combined with our analytical precision, creates a powerful platform for developing tomorrow’s healthcare solutions,” added Professor Mikael Kubista, co-founder of Precision BioAnalytics.
This venture partnership is more than a financial investment. It signals a growing integration of infrastructure and advanced analytics that supports the entire ATMP value chain — from early research to clinical translation and commercialization.
For Sweden and the wider Nordic region, collaborations like this reinforce the ecosystem’s position as a hub for ATMP innovation and clinical development.
Learn more: CCRM Nordic | Precision BioAnalytics
